Charles River Laboratories International (CRL) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Apr. 01, 2017	Apr. 24, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL INC
Entity Central Index Key	1,100,682
Current Fiscal Year End Date	--12-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Apr. 1, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		47,639,367

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Income Statement [Abstract]
Service revenue	$ 304,531	$ 220,701
Product revenue	141,232	134,167
Total revenue	445,763	354,868
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)	206,820	147,349
Cost of products sold (excluding amortization of intangible assets)	67,244	66,751
Selling, general and administrative	91,490	82,944
Amortization of intangible assets	10,737	6,352
Operating income	69,472	51,472
Other income (expense):
Interest income	202	263
Interest expense	(6,983)	(4,211)
Other income (expense), net	15,356	4,026
Income from continuing operations, before income taxes	78,047	51,550
Provision for income taxes	31,084	13,975
Income from continuing operations, net of income taxes	46,963	37,575
Loss from discontinued operations, net of income taxes	(4)	(26)
Net income	46,959	37,549
Less: Net income attributable to noncontrolling interests	181	406
Net income attributable to common shareholders	$ 46,778	$ 37,143
Basic:
Continuing operations attributable to common shareholders (in dollars per share)	$ 0.98	$ 0.80
Discontinued operations (in dollars per share)	0	0
Net income attributable to common shareholders (in dollars per share)	0.98	0.80
Diluted:
Continuing operations attributable to common shareholders (in dollars per share)	0.97	0.78
Discontinued operations (in dollars per share)	0	0
Net income attributable to common shareholders (in dollars per share)	$ 0.97	$ 0.78

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 46,959	$ 37,549
Other comprehensive income (loss):
Foreign currency translation adjustment and other	11,221	(7,796)
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	854	390
Comprehensive income, before income taxes	59,034	30,143
Income tax expense related to items of other comprehensive income (Note 8)	226	142
Comprehensive income, net of income taxes	58,808	30,001
Less: Comprehensive income related to noncontrolling interests, net of income taxes	298	127
Comprehensive income attributable to common shareholders, net of income taxes	$ 58,510	$ 29,874

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 131,524	$ 117,626
Trade receivables, net	383,748	364,050
Inventories	98,482	95,833
Prepaid assets	42,495	34,315
Other current assets	43,872	45,008
Total current assets	700,121	656,832
Property, plant and equipment, net	746,951	755,827
Goodwill	756,022	787,517
Client relationships and Other intangible assets, net	369,813	394,448
Deferred tax assets	30,306	28,746
Other assets	93,862	88,430
Total assets	2,697,075	2,711,800
Current liabilities:
Current portion of long-term debt and capital leases	27,308	27,313
Accounts payable	60,987	68,485
Accrued compensation	63,309	93,471
Deferred revenue	127,591	127,731
Accrued liabilities	84,093	84,470
Other current liabilities	18,460	26,500
Current liabilities of discontinued operations	1,626	1,623
Total current liabilities	383,374	429,593
Long-term debt, net and capital leases	1,170,063	1,207,696
Deferred tax liabilities	83,930	55,717
Other long-term liabilities	160,663	159,239
Long-term liabilities of discontinued operations	5,300	5,771
Total liabilities	1,803,330	1,858,016
Commitments and contingencies
Redeemable noncontrolling interest	14,698	14,659
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 87,132 shares issued and 47,635 shares outstanding as of April 1, 2017 and 86,301 shares issued and 47,363 shares outstanding as of December 31, 2016	871	863
Additional paid-in capital	2,506,696	2,477,371
Retained earnings	212,081	165,303
Treasury stock, at cost 39,497 shares and 38,938 shares as of April 1, 2017 and December 31, 2016, respectively	(1,601,185)	(1,553,005)
Accumulated other comprehensive loss	(242,032)	(253,764)
Total equity attributable to common shareholders	876,431	836,768
Noncontrolling interests	2,616	2,357
Total equity	879,047	839,125
Total liabilities, redeemable noncontrolling interest and equity	2,697,075	2,711,800
Client relationships, net
Current assets:
Client relationships and Other intangible assets, net	299,477	320,157
Other intangible assets, net
Current assets:
Client relationships and Other intangible assets, net	$ 70,336	$ 74,291

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Apr. 01, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	87,132,000	86,301,000
Common stock, shares outstanding (in shares)	47,635,000	47,363,000
Treasury stock (in shares)	39,497,000	38,938,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Cash flows relating to operating activities
Net income	$ 46,959	$ 37,549
Less: Loss from discontinued operations, net of income taxes	(4)	(26)
Income from continuing operations, net of income taxes	46,963	37,575
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	32,411	24,655
Stock-based compensation	9,486	9,941
Deferred income taxes	26,273	12,522
Gain on divestiture	(10,577)	0
Other, net	462	(1,252)
Changes in assets and liabilities:
Trade receivables, net	(21,062)	(16,279)
Inventories	(2,593)	(3,081)
Accounts payable	(6,258)	9,352
Accrued compensation	(30,399)	(16,025)
Other assets and liabilities, net	(10,677)	(11,564)
Net cash provided by operating activities	34,029	45,844
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	0	(318)
Capital expenditures	(15,920)	(8,250)
Purchases of investments	(6,698)	(6,395)
Proceeds from sale of investments and distributions from venture capital investments	3,135	5,700
Proceeds from divestiture	72,462	0
Other, net	17	2,821
Net cash provided by (used in) investing activities	52,996	(6,442)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	112,724	49,423
Proceeds from exercises of stock options	19,723	12,514
Payments on long-term debt, revolving credit facility and capital lease obligations	(158,140)	(49,409)
Purchase of treasury stock	(48,180)	(12,147)
Other, net	(451)	(675)
Net cash used in financing activities	(74,324)	(294)
Discontinued operations
Net cash used in operating activities from discontinued operations	(473)	(489)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	1,705	739
Net change in cash, cash equivalents, and restricted cash	13,933	39,358
Cash, cash equivalents, and restricted cash, beginning of period	119,894	119,963
Cash, cash equivalents, and restricted cash, end of period	133,827	159,321
Supplemental cash flow information:
Cash and cash equivalents	131,524	157,375
Restricted cash included in Other current assets	538	159
Restricted cash included in Other assets	$ 1,765	$ 1,787

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission. The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2016 . The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. The Company has reclassified certain amounts in the unaudited condensed consolidated statements of cash flow for prior periods to conform to current year presentation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, redeemable noncontrolling interest, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on a 52-week year, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53 rd week was included in the fourth quarter of fiscal year 2016, which is occasionally necessary to align with a December 31 calendar year-end. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K for fiscal year 2016 . Newly Adopted Accounting Pronouncements In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-18, “Restricted Cash.” The standard addresses the classification and presentation of restricted cash and restricted cash equivalents within the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. During the three months ended April 1, 2017 , the Company elected to early adopt this standard and applied the changes retrospectively to all prior periods presented in its unaudited condensed consolidated statements of cash flows. The Company historically excluded restricted cash balances, recorded in current and long-term other assets, from cash and cash equivalents within the unaudited consolidated statements of cash flows, reflecting transfers between cash, cash equivalents, and restricted cash as a cash flow classified within cash flows relating to operating activities. As a result of the adoption of this standard, the Company combined restricted cash balances of $1.9 million and $2.0 million as of March 26, 2016 and December 26, 2015, respectively, with cash and cash equivalents when reconciling the beginning and ending balances within the unaudited condensed consolidated statements of cash flows for the three months ended March 26, 2016 . In August 2016, the FASB issued ASU 2016-15, “ Classification of Certain Cash Receipts and Cash Payments.” The standard addresses the classification of certain transactions within the statement of cash flows, including cash payments for debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and distributions received from equity method investments. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. During the three months ended April 1, 2017 , the Company elected to early adopt this standard and applied the changes retrospectively to all prior periods presented within its unaudited condensed consolidated statements of cash flows. The adoption of this standard had no impact within the unaudited condensed consolidated statement of cash flows for the three months ended March 26, 2016 . In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The standard reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification within the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted this standard d uring the three months ended April 1, 2017 , and applied the changes as required by each amendment to its consolidated financial statements and related disclosures. Under ASU 2016-09, the Company adopted the amendment to recognize excess tax benefits and tax deficiencies in the consolidated statement of income on a prospective basis, the amendment to present excess tax benefits within operating activities within the unaudited condensed consolidated statements of cash flows on a retrospective basis, and elected to change its accounting policy to account for forfeitures when they occur on a modified retrospective basis. The adoption to recognize excess tax benefits and tax deficiencies within the unaudited condensed consolidated statements of income on a prospective basis could result in fluctuations in the effective tax rate period-over-period depending on how many awards vest and the volatility of the stock price. During the three months ended April 1, 2017 , the impact to the provision for income taxes within the unaudited condensed consolidated statements of income was an excess tax benefit of $ 7.5 million . Further, for the three months ended April 1, 2017 , the Company excluded the effect of windfall tax benefits from the hypothetical proceeds used to calculate the repurchase of shares under the treasury stock method for the calculation of diluted earnings per share. The adoption of the amendment to present excess tax benefits within operating activities within the unaudited condensed consolidated statements of cash flows on a retrospective basis resulted in the reclassification of a cash inflow of $7.4 million from cash provided by financing activities to cash provided by operating activities for the three months ended March 26, 2016 . The Company had previously classified cash paid for tax withholding purposes as a financing activity within the unaudited condensed consolidated statements of cash flows; therefore, there was no change related to this requirement under the amendment. The Company’s election to change its accounting policy to account for forfeitures when they occur on a modified retrospective basis resulted in an immaterial impact to its consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2017, the FASB issued ASU 2017-07, “Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” The standard requires an employer to disaggregate the service cost component from the other components of net benefit cost and provides explicit guidance on the presentation of the service cost component and the other components of net benefit cost in the statement of income. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years, and should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost in the statement of income. Early adoption is permitted within the first interim period of the fiscal year. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. The ASU is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-01, “Clarifying the Definition of a Business.” The standard clarifies the definition of a business by adding guidance to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted for certain transactions. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In October 2016, the FASB issued ASU 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory.” The standard requires the immediate recognition of tax effects for an intra-entity asset transfer other than inventory. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures, but expects to recognize substantially all of its leases on the balance sheet by recording a right-to-use asset and a corresponding lease liability. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. The standard will require an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will be effective for annual and interim periods beginning after December 15, 2017. The Company formed an implementation team during fiscal year 2016 to oversee adoption of the new standard. The implementation team has completed its initial assessment of the new standard, including a detailed review of the Company’s contract portfolio, revenue streams to identify potential differences in accounting as a result of the new standard, and selected the modified retrospective transition method. The Company continues to assess the impact on the existing revenue accounting policies, newly required financial statement disclosures, and executing on the project plan. Currently, the Company is finalizing contract reviews, working through anticipated changes to systems and business processes, and internal controls to support the adoption of the new standard.

Business Acquisitions and Dives

Business Acquisitions and Divestiture	3 Months Ended
	Apr. 01, 2017
Business Combinations [Abstract]
BUSINESS ACQUISITIONS AND DIVESTITURE	BUSINESS ACQUISITIONS AND DIVESTITURE Agilux On September 28, 2016 , the Company acquired Agilux Laboratories, Inc. (Agilux), a contract research organization (CRO) that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. The acquisition supports the Company’s strategy to offer clients a broader, integrated portfolio that provides services continuously from the earliest stages of drug research through the non-clinical development process. The purchase price for Agilux was $64.9 million in cash and was funded by borrowings on the Company’s revolving credit facility. The business is reported as part of the Company’s DSA reportable segment. The purchase price allocation of $62.0 million , net of $2.9 million of cash acquired, was as follows: September 28, 2016 (in thousands) Trade receivables (contractual amount of $4,799) $ 4,799 Other current assets (excluding cash) 1,509 Property, plant and equipment 3,907 Other long-term assets 11 Definite-lived intangible assets 21,900 Goodwill 43,899 Current liabilities (3,987 ) Long-term liabilities (10,013 ) Total purchase price allocation $ 62,025 The purchase price allocations are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,700 17 Other intangible assets 5,200 4 Total definite-lived intangible assets $ 21,900 14 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA businesses from customers and technology introduced through Agilux and the assembled workforce of the acquired business. The goodwill attributable to Agilux is not deductible for tax purposes. The Company incurred $0.2 million in transaction and integration costs in connection with the acquisition during the three months ended April 1, 2017 , which were included in selling, general and administrative expenses, within the unaudited condensed consolidated statements of income. Blue Stream On June 27, 2016 , the Company acquired Blue Stream Laboratories, Inc. (Blue Stream), an analytical CRO supporting the development of complex biologics and biosimilars. Combining Blue Stream with the Company’s existing discovery, safety assessment, and biologics capabilities creates a leading CRO that has the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization. The purchase price for Blue Stream was $11.7 million , including $3.0 million in contingent consideration, and was subject to certain customary adjustments. The acquisition was funded by borrowings on the Company’s revolving credit facility. The business is reported in the Company’s Manufacturing reportable segment. The contingent consideration is a one-time payment that could become payable based on the achievement of a revenue target. If achieved, the payment will become due in the third quarter of fiscal year 2017. The aggregate, undiscounted amount of contingent consideration that the Company may pay is $3.0 million . The Company estimated the fair value of this contingent consideration based on a probability-weighted set of outcomes. The purchase price allocation of $11.7 million , net of a non-significant amount of cash acquired, was as follows: June 27, 2016 (in thousands) Trade receivables (contractual amount of $1,104) $ 1,104 Other current assets (excluding cash) 15 Property, plant and equipment 912 Other long-term assets 187 Definite-lived intangible assets 1,230 Goodwill 10,477 Current liabilities (1,132 ) Long-term liabilities (1,044 ) Total purchase price allocation $ 11,749 The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 650 10 Other intangible assets 580 5 Total definite-lived intangible assets $ 1,230 7 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s Manufacturing business from customers and technology introduced through Blue Stream, the assembled workforce of the acquired business, expected synergies, and the development of future proprietary processes. The goodwill attributable to Blue Stream is not deductible for tax purposes. The Company incurred non-significant transaction and integration costs in connection with the acquisition during the three months ended April 1, 2017 , which were included in selling, general and administrative expenses, within the unaudited condensed consolidated statements of income. WIL Research On April 4, 2016 , the Company acquired WIL Research, a provider of safety assessment and CDMO services to biopharmaceutical and agricultural and industrial chemical companies worldwide. The acquisition enhanced the Company’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum. The purchase price for WIL Research was $604.8 million , including assumed liabilities of $0.4 million . The purchase price included payment for actual working capital of the acquired business. The acquisition was funded by cash on hand and borrowings on the Company’s amended credit facility. See Note 7, “Long-Term Debt and Capital Lease Obligations.” WIL Research’s safety assessment and CDMO businesses are reported in the Company’s DSA and Manufacturing reportable segments, respectively. On February 10, 2017, the Company divested the CDMO business. The purchase price allocation of $577.4 million , net of $27.4 million of cash acquired, was as follows: April 4, 2016 (in thousands) Trade receivables (contractual amount of $48,625) $ 48,157 Inventories 2,296 Other current assets (excluding cash) 3,814 Property, plant and equipment 129,066 Other long-term assets 1,060 Definite-lived intangible assets 164,800 Goodwill 330,175 Deferred revenue (39,103 ) Other current liabilities (27,386 ) Long-term liabilities (35,488 ) Total purchase price allocation $ 577,391 From the date of the acquisition through April 1, 2017 , the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 137,500 15 Developed technology 20,700 3 Backlog 6,600 1 Total definite-lived intangible assets $ 164,800 13 The goodwill resulting from the transaction, $19.0 million of which was deductible for tax purposes due to a prior asset acquisition, was primarily attributed to the potential growth of the Company’s DSA and Manufacturing businesses from clients introduced through WIL Research, the assembled workforce of the acquired business, and expected cost synergies. Subsequent to the divestiture of the CDMO business on February 10, 2017 , $14.8 million of the goodwill from the transaction is deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $0.5 million and $4.0 million for the three months ended April 1, 2017, and March 26, 2016 , respectively, which were included in selling, general and administrative expenses, within the unaudited condensed consolidated statements of income. Contract Manufacturing On February 10, 2017 , the Company completed the divestiture of its CDMO business to Quotient Clinical Ltd., based in London, England, for $75.0 million in proceeds, net of $0.6 million in cash and cash equivalents transferred in conjunction with the sale and $0.3 million of estimated working capital adjustments. The CDMO business was acquired in April 2016 as part of the acquisition of WIL Research and was reported in the Company’s Manufacturing reportable segment . Following a strategic review that was finalized subsequent to December 31, 2016, the Company determined that the CDMO business was not optimized within the Company’s portfolio at its current scale, and that the capital could be better deployed in other long-term growth opportunities. During the three months ended April 1, 2017 , the Company recorded a gain on the divestiture of the CDMO business of $10.6 million , which was included in other income (expense), net. As of February 10, 2017 , the carrying amounts of the major classes of assets and liabilities associated with the divestiture of the CDMO business were as follows: February 10, 2017 (in thousands) Assets Current assets $ 5,505 Property, plant and equipment, net 11,174 Goodwill 35,857 Long-term assets 17,154 Total assets $ 69,690 Liabilities Deferred revenue $ 4,878 Other current liabilities 1,158 Total liabilities $ 6,036

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Apr. 01, 2017
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION The composition of trade receivables, net is as follows: April 1, 2017 December 31, 2016 (in thousands) Client receivables $ 301,246 $ 283,997 Unbilled revenue 84,843 82,203 Total 386,089 366,200 Less: Allowance for doubtful accounts (2,341 ) (2,150 ) Trade receivables, net $ 383,748 $ 364,050 The composition of inventories is as follows: April 1, 2017 December 31, 2016 (in thousands) Raw materials and supplies $ 18,401 $ 18,893 Work in process 10,851 13,681 Finished products 69,230 63,259 Inventories $ 98,482 $ 95,833 The composition of other current assets is as follows: April 1, 2017 December 31, 2016 (in thousands) Investments $ 3,872 $ 3,771 Prepaid income taxes 39,462 40,705 Restricted cash 538 532 Other current assets $ 43,872 $ 45,008 The composition of other assets is as follows: April 1, 2017 December 31, 2016 (in thousands) Life insurance policies $ 30,759 $ 29,456 Venture capital investments 48,789 45,331 Restricted cash 1,765 1,736 Other 12,549 11,907 Other assets $ 93,862 $ 88,430 The composition of other current liabilities is as follows: April 1, 2017 December 31, 2016 (in thousands) Accrued income taxes $ 17,880 $ 25,621 Other 580 879 Other current liabilities $ 18,460 $ 26,500 The composition of other long-term liabilities is as follows: April 1, 2017 December 31, 2016 (in thousands) Long-term pension liability $ 89,047 $ 89,984 Accrued executive supplemental life insurance retirement plan and deferred compensation plan 33,213 32,880 Other 38,403 36,375 Other long-term liabilities $ 160,663 $ 159,239

Venture Capital Investments

Venture Capital Investments	3 Months Ended
	Apr. 01, 2017
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL INVESTMENTS	VENTURE CAPITAL INVESTMENTS The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from 0.7% to 12.0% . The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity or cost method of accounting. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. The Company accounts for the investments in limited liability companies, which are not variable interest entities, under the equity method of accounting. The Company’s total commitments to the entities as of April 1, 2017 , were $84.8 million , of which the Company funded $42.0 million through April 1, 2017 . During the three months ended April 1, 2017 , the Company received dividends of $4.4 million from the entities. During the three months ended March 26, 2016 , the Company received no dividends from the entities. The Company recognized a gain of $4.2 million and a gain of $3.1 million related to these investments for the three months ended April 1, 2017, and March 26, 2016 , respectively.

Fair Value

Fair Value	3 Months Ended
	Apr. 01, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company has certain assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy: • Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access; • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates; • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value hierarchy level is determined by asset and liability class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the three months ended April 1, 2017, and March 26, 2016 , there were no transfers between levels. Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows: • Cash equivalents - Valued at market prices determined through third-party pricing services; • Mutual funds - Valued at the unadjusted quoted net asset value of shares held by the Company; • Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates; • Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments; • Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes. Assets and liabilities measured at fair value on a recurring basis are summarized below: April 1, 2017 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 21 $ — $ 21 Other assets: Life insurance policies — 23,386 — 23,386 Total assets measured at fair value $ — $ 23,407 $ — $ 23,407 Other current liabilities: Contingent consideration $ — $ — $ 3,201 $ 3,201 Total liabilities measured at fair value $ — $ — $ 3,201 $ 3,201 December 31, 2016 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 21 $ — $ 21 Other assets: Life insurance policies — 22,121 — 22,121 Total assets measured at fair value $ — $ 22,142 $ — $ 22,142 Other current liabilities: Contingent consideration $ — $ — $ 3,621 $ 3,621 Total liabilities measured at fair value $ — $ — $ 3,621 $ 3,621 Contingent Consideration The following table provides a rollforward of the contingent consideration related to the business acquisitions. See Note 2, “Business Acquisitions and Divestiture.” Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 3,621 $ 1,370 Additions — 600 Payments (406 ) (674 ) Total gains or losses (realized/unrealized): Reversal of previously recorded contingent liability and change in fair value (14 ) 18 Ending balance $ 3,201 $ 1,314 The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Increases or decreases in any of the probabilities of success would result in a higher or lower fair value measurement, respectively. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively. Debt Instruments The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Apr. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 31, 2016 Acquisitions / (Divestitures) Transfers Foreign Exchange April 1, 2017 (in thousands) DSA $ 563,476 $ (427 ) $ — $ 3,074 $ 566,123 RMS 56,397 — — 182 56,579 Manufacturing 167,644 (35,857 ) — 1,533 133,320 Total $ 787,517 $ (36,284 ) $ — $ 4,789 $ 756,022 The reduction of goodwill of $ 35.9 million relates to the divestiture of the CDMO business within the Manufacturing reportable segment. Intangible Assets, Net The following table displays intangible assets, net by major class: April 1, 2017 December 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 7,782 $ (7,351 ) $ 431 $ 8,370 $ (6,390 ) $ 1,980 Technology 72,241 (17,171 ) 55,070 71,425 (14,314 ) 57,111 Trademarks and trade names 8,271 (4,204 ) 4,067 8,177 (4,124 ) 4,053 Other 16,794 (6,026 ) 10,768 16,775 (5,628 ) 11,147 Other intangible assets 105,088 (34,752 ) 70,336 104,747 (30,456 ) 74,291 Client relationships 506,406 (206,929 ) 299,477 519,123 (198,966 ) 320,157 Intangible assets $ 611,494 $ (241,681 ) $ 369,813 $ 623,870 $ (229,422 ) $ 394,448 During the three months ended April 1, 2017 , the Company divested the CDMO business, which resulted in a net decrease of $ 16.8 million and $ 0.3 million to client relationships and backlog, respectively. During the three months ended March 26, 2016 , the Company determined that the carrying values of certain DSA intangible assets were not recoverable and recorded an impairment charge of $ 1.9 million , which was included in costs of services provided (excluding amortization of intangible assets) within the Company’s unaudited condensed consolidated statements of income.

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Lease Obligations	3 Months Ended
	Apr. 01, 2017
Debt Disclosure [Abstract]
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS	LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS Long-Term Debt Long-term debt, net consists of the following: April 1, 2017 December 31, 2016 (in thousands) Term loans $ 625,625 $ 633,750 Revolving credit facility 544,954 578,759 Other long-term debt 3,634 185 Total debt 1,174,213 1,212,694 Less: current portion of long-term debt (24,562 ) (24,560 ) Long-term debt 1,149,651 1,188,134 Debt discount and debt issuance costs (7,163 ) (7,633 ) Long-term debt, net $ 1,142,488 $ 1,180,501 As of April 1, 2017 and December 31, 2016 , the weighted average interest rate on the Company’s debt was 2.07% and 1.89% , respectively. On March 30, 2016, the Company amended and restated its $ 1.3 billion credit facility creating a $ 1.65 billion credit facility ($ 1.65B Credit Facility) which (1) extends the maturity date for the credit facility and (2) makes certain other amendments in connection with the Company’s acquisition of WIL Research. The amendment was accounted for as a debt modification with a partial extinguishment of debt. In connection with the amendment and restatement, the Company capitalized approximately $ 3.3 million and expensed approximately $ 1.4 million of debt issuance costs. The $ 1.65B Credit Facility provides for a $ 650.0 million term loan and a $ 1.0 billion multi-currency revolving facility. The term loan facility matures in 19 quarterly installments with the last installment due March 30, 2021. The revolving facility matures on March 30, 2021, and requires no scheduled payment before that date. Under specified circumstances, the Company has the ability to increase the term loan and/or revolving line of credit by up to $ 500.0 million in the aggregate. The interest rates applicable to the term loan and revolving loans under the $ 1.65B Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50% , or (3) the one-month adjusted LIBOR rate plus 1.0% ) or the adjusted LIBOR rate, plus an interest rate margin based upon the Company’s leverage ratio. The $ 1.65B Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0 with step downs to 3.50 to 1.0 by the last day of the three months ended December 30, 2017. As of April 1, 2017 , the Company was compliant with all covenants. The obligations of the Company under the $ 1.65B Credit Facility are collateralized by substantially all of the assets of the Company. Letters of Credit As of April 1, 2017 , and December 31, 2016 , the Company had $4.9 million in outstanding letters of credit. Capital Lease Obligations The Company’s capital lease obligations amounted to $30.3 million and $29.9 million as of April 1, 2017 , and December 31, 2016 , respectively.

Equity and Redeemable Noncontro

Equity and Redeemable Noncontrolling Interest	3 Months Ended
	Apr. 01, 2017
Equity [Abstract]
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST	EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Numerator: Income from continuing operations, net of income taxes $ 46,963 $ 37,575 Loss from discontinued operations, net of income taxes (4 ) (26 ) Less: Net income attributable to noncontrolling interests 181 406 Net income attributable to common shareholders $ 46,778 $ 37,143 Denominator: Weighted-average shares outstanding - Basic 47,546 46,642 Effect of dilutive securities: Stock options, restricted stock units, performance share units and restricted stock 875 975 Weighted-average shares outstanding - Diluted 48,421 47,617 Options to purchase approximately 1.1 million and 1.0 million shares for the three months ended April 1, 2017 and March 26, 2016 , respectively, as well as an insignificant number of restricted stock, restricted stock units (RSUs), and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted average shares outstanding for both the three months ended April 1, 2017 and March 26, 2016 excluded the impact of approximately 1.1 million shares of non-vested restricted stock and restricted stock units. Treasury Shares During the three months ended April 1, 2017 , the Company repurchased 0.4 million shares totaling $32.1 million under its authorized stock repurchase program. The Company did not repurchase any shares under its authorized stock repurchase program in the three months ended March 26, 2016 . As of April 1, 2017 , the Company had $37.6 million remaining on the authorized stock repurchase program. On May 9, 2017, the Company’s Board of Directors increased the stock repurchase authorization by $ 150.0 million , to an aggregate amount of $ 1.3 billion . The Company’s stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, RSUs, and PSUs in order to satisfy individual statutory tax withholding requirements. During the three months ended April 1, 2017 , and March 26, 2016 , the Company acquired approximately 0.2 million shares for $16.1 million and approximately 0.2 million shares for $12.1 million , respectively. Accumulated Other Comprehensive Income Changes to each component of accumulated other comprehensive income, net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 31, 2016 $ (154,595 ) $ (99,169 ) $ (253,764 ) Other comprehensive loss before reclassifications 11,104 — 11,104 Amounts reclassified from accumulated other comprehensive income (loss) — 854 854 Net current period other comprehensive income 11,104 854 11,958 Income tax expense — 226 226 April 1, 2017 $ (143,491 ) $ (98,541 ) $ (242,032 ) Nonredeemable Noncontrolling Interests The Company has investments in several entities whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over these entities. The interests of the respective noncontrolling parties in these entities have been recorded as noncontrolling interests. The activity within the nonredeemable noncontrolling interests was non-significant during the three months ended April 1, 2017 , and March 26, 2016 . Redeemable Noncontrolling Interest The Company’s redeemable noncontrolling interest resulted from an acquisition of a 75% ownership interest in Vital River in January 2013 and a purchase of an additional 12% equity interest in Vital River in July 2016, totaling an ownership of 87% . Prior to the purchase of an additional 12% equity interest on July 7, 2016, the redeemable noncontrolling interest was reported at fair value. Concurrent with the purchase of an additional equity interest, the original agreement was amended providing the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 13% equity interest at a contractually defined redemption value, subject to a redemption floor (embedded derivative). These rights are exercisable beginning in 2019 and are accelerated in certain events. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($ 14.1 million as of April 1, 2017 ) and its carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 13% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheet, which is presented above the equity section and below liabilities. The agreement does not limit the amount that the Company could be required to pay to purchase the remaining 13% equity interest. The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interest: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 14,659 $ 28,008 Purchase of additional equity interest — — Total gains or losses (realized/unrealized): Net income (loss) attributable to noncontrolling interest (78 ) 198 Foreign currency translation 117 (186 ) Change in fair value, included in additional paid-in capital — 724 Ending balance $ 14,698 $ 28,744

Income Taxes

Income Taxes	3 Months Ended
	Apr. 01, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended April 1, 2017, and March 26, 2016 was 39.8% and 27.1% , respectively. For the three months ended April 1, 2017 , the increase was primarily attributable to the tax on the gain on the divesture of the CDMO business of $18.0 million , offset by the excess tax benefit associated with the stock compensation of $7.5 million as a result of the adoption of ASU 2016-09. During the three months ended April 1, 2017 , the Company’s unrecognized tax benefits increased by $0.9 million to $25.1 million , primarily due to an additional quarter of Canadian Scientific Research and Experimental Development credit reserves and unfavorable foreign exchange movement. The amount of unrecognized income tax benefits that would impact the effective tax rate increased by $0.8 million to $22.2 million , for the same reasons noted above. As of April 1, 2017 , and March 26, 2016 , the amount of accrued interest and penalties on unrecognized tax benefits was $1.9 million and $ 0.2 million , respectively. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by up to $5.0 million over the next twelve-month period, primarily as a result of the outcome of a pending tax ruling and competent authority proceedings. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits in jurisdictions including the U.S., U.K., China, Japan, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2013. The Company and certain of its subsidiaries have ongoing tax controversies with various tax authorities in the U.S., Canada, Germany, and France. The Company does not believe that resolution of these controversies will have a material impact on its financial position or results of operations. In accordance with the Company’s policy, the remaining undistributed earnings of its non-U.S. subsidiaries remain indefinitely reinvested as of April 1, 2017 , as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free. Income tax expense related to change in unrecognized pension gains, losses, and prior service costs was $0.2 million and $0.1 million or the three months ended April 1, 2017, and March 26, 2016 , respectively.

Pension and Other Post-Retireme

Pension and Other Post-Retirement Benefit Plans	3 Months Ended
	Apr. 01, 2017
Compensation and Retirement Disclosure [Abstract]
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS The following table provides the components of net periodic cost for the Company’s Pension, Deferred Compensation, and Executive Supplemental Life Insurance Retirement plans: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Service cost $ 754 $ 554 Interest cost 2,826 3,364 Expected return on plan assets (3,450 ) (3,992 ) Amortization of prior service credit (119 ) (144 ) Amortization of net loss 966 546 Net periodic cost $ 977 $ 328 The net periodic cost for the Company’s post-retirement benefit plan for the three months ended April 1, 2017 and March 26, 2016 was non-significant.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Apr. 01, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs, and PSUs. The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Cost of revenue $ 1,546 $ 1,682 Selling, general and administrative 7,940 8,259 Stock-based compensation, before income taxes 9,486 9,941 Provision for income taxes (3,308 ) (3,514 ) Stock-based compensation, net of income taxes $ 6,178 $ 6,427 During the three months ended April 1, 2017 , the Company issued approximately 0.6 million stock options with a per share weighted average grant date fair value of $18.27 , approximately 0.2 million RSUs with a per share weighted average grant date fair value of $88.05 , and approximately 0.2 million PSUs with a per share weighted average grant date fair value of $99.24 . The maximum number of common shares to be issued upon vesting of PSUs granted during the three months ended April 1, 2017 , is approximately 0.4 million .

Foreign Currency Contracts

Foreign Currency Contracts	3 Months Ended
	Apr. 01, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FOREIGN CURRENCY CONTRACTS	FOREIGN CURRENCY CONTRACTS The Company enters into foreign exchange forward contracts to limit its foreign currency exposure related to intercompany loans that are not of a long-term investment nature. These contracts are recorded at fair value in the Company’s unaudited condensed consolidated balance sheet and are not designated as hedging instruments. Any gains or losses on such contracts are immediately recognized in other income (expense), net, and are largely offset by the remeasurement of the underlying intercompany loan balances. The Company did not have any foreign currency contracts open as of April 1, 2017 , and December 31, 2016 . The following table summarizes gains recognized on foreign exchange forward contracts related to intercompany loans denominated in Euros on the Company’s unaudited condensed consolidated statements of income: Three Months Ended Location of Gain (Loss) April 1, 2017 March 26, 2016 (in thousands) Other income (expense), net $ — $ 2,243

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Apr. 01, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition. In May 2013, the Company commenced an investigation into inaccurate billing with respect to certain government contracts. The Company promptly reported these matters to the relevant government contracting officers, the Department of Health and Human Services’ Office of the Inspector General, and the Department of Justice, and the Company is cooperating with these agencies to ensure the proper repayment and resolution of this matter. The Company previously identified approximately $ 1.5 million of excess amounts billed on these contracts since January 1, 2007, and recorded a liability for such amount. Based on its ongoing discussions with the government, the Company recorded an additional charge of $ 0.3 million during the fiscal year 2016. On March 13, 2017, the Company entered into a final settlement with the Department of Justice and the Department of Health and Human Services’ Office of the Inspector General and pursuant to the settlement paid the government $ 1.8 million to resolve the matter. Lease Commitments During the three months ended April 1, 2017 , the Company assumed or entered into new lease agreements or exercised options to extend the lease terms for certain existing leases. As a result, the Company’s lease obligations through 2025 increased by $6.1 million .

Restructuring and Asset Impairm

Restructuring and Asset Impairment Restructuring and Asset Impairment	3 Months Ended
	Apr. 01, 2017
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENT	RESTRUCTURING AND ASSET IMPAIRMENTS Workforce Reductions In recent fiscal years the Company has been undertaking productivity improvement initiatives at various facilities. The following table provides a rollforward of the Company’s severance and transition costs liabilities related to those initiatives: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 3,680 $ 2,969 Expense 1,017 21 Payments / utilization (1,273 ) (413 ) Foreign currency adjustments 27 (56 ) Ending balance $ 3,451 $ 2,521 As of April 1, 2017 and March 26, 2016 , $3.5 million and $2.4 million of severance and other personnel related costs liability, respectively, was included in accrued compensation. As of March 26, 2016 there was a non-significant amount included in other long-term liabilities on the Company's unaudited condensed consolidated balance sheets. The following table presents severance and transition costs by classification on the unaudited condensed consolidated statements of income: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Cost of services provided and products sold (excluding amortization of intangible assets) $ 923 $ 21 Selling, general and administrative 94 — Total severance and transition costs $ 1,017 $ 21 The following presents severance and transition related costs by reportable segment: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) DSA $ 196 $ 21 Manufacturing 821 — Total severance and transition costs $ 1,017 $ 21 Facilities During the three months ended April 1, 2017 , the Company continued the consolidation of certain DSA facilities in the U.S., Ireland and the United Kingdom. As a result, an asset impairment charge of $0.1 million and a gain of $0.4 million was recorded related to the consolidation plans. During the three months ended March 26, 2016 , the Company continued a consolidation of certain RMS and DSA facilities in the U.S. and the United Kingdom. As a result, the Company recorded $0.2 million of accelerated depreciation related to the consolidation plans.

Segment Information

Segment Information	3 Months Ended
	Apr. 01, 2017
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company revised the composition of its reportable segments during the three months ended June 25, 2016. See Note 1, “Basis of Presentation.” The Company reported segment results on this basis retrospectively for all comparable prior periods presented. The following table presents revenue and other financial information by reportable segment: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) RMS Revenue $ 127,161 $ 123,339 Operating income 37,711 36,386 Depreciation and amortization 5,092 5,250 Capital expenditures 2,603 1,053 DSA Revenue $ 227,758 $ 157,983 Operating income 38,660 30,830 Depreciation and amortization 19,369 11,957 Capital expenditures 8,323 4,707 Manufacturing Revenue $ 90,844 $ 73,546 Operating income 26,601 19,615 Depreciation and amortization 5,962 5,976 Capital expenditures 2,292 2,129 For the three months ended April 1, 2017, and March 26, 2016 , reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures April 1, 2017 March 26, 2016 April 1, 2017 March 26, 2016 April 1, 2017 March 26, 2016 (in thousands) Total reportable segments $ 102,972 $ 86,831 $ 30,423 $ 23,183 $ 13,218 $ 7,889 Unallocated corporate (33,500 ) (35,359 ) 1,988 1,472 2,702 361 Total consolidated $ 69,472 $ 51,472 $ 32,411 $ 24,655 $ 15,920 $ 8,250 Revenue for each significant product or service offering is as follows: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) RMS $ 127,161 $ 123,339 DSA 227,758 157,983 Manufacturing 90,844 73,546 Total revenue $ 445,763 $ 354,868 A summary of unallocated corporate expense consists of the following : Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Stock-based compensation $ 5,583 $ 6,108 Compensation, benefits, and other employee-related expenses 14,962 12,541 External consulting and other service expenses 5,767 5,176 Information technology 2,393 3,132 Depreciation 1,987 1,472 Acquisition and integration 21 3,763 Other general unallocated corporate 2,787 3,167 Total unallocated corporate expense $ 33,500 $ 35,359 Other general unallocated corporate expense consists of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

Basis of Presentation - Signifi

Basis of Presentation - Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal Period	The Company’s fiscal year is typically based on a 52-week year, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53 rd week was included in the fourth quarter of fiscal year 2016, which is occasionally necessary to align with a December 31 calendar year-end.
Use of Estimates	The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, redeemable noncontrolling interest, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Consolidation	The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Newly Issued Accounting Pronouncements	In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-18, “Restricted Cash.” The standard addresses the classification and presentation of restricted cash and restricted cash equivalents within the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. During the three months ended April 1, 2017 , the Company elected to early adopt this standard and applied the changes retrospectively to all prior periods presented in its unaudited condensed consolidated statements of cash flows. The Company historically excluded restricted cash balances, recorded in current and long-term other assets, from cash and cash equivalents within the unaudited consolidated statements of cash flows, reflecting transfers between cash, cash equivalents, and restricted cash as a cash flow classified within cash flows relating to operating activities. As a result of the adoption of this standard, the Company combined restricted cash balances of $1.9 million and $2.0 million as of March 26, 2016 and December 26, 2015, respectively, with cash and cash equivalents when reconciling the beginning and ending balances within the unaudited condensed consolidated statements of cash flows for the three months ended March 26, 2016 . In August 2016, the FASB issued ASU 2016-15, “ Classification of Certain Cash Receipts and Cash Payments.” The standard addresses the classification of certain transactions within the statement of cash flows, including cash payments for debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and distributions received from equity method investments. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. During the three months ended April 1, 2017 , the Company elected to early adopt this standard and applied the changes retrospectively to all prior periods presented within its unaudited condensed consolidated statements of cash flows. The adoption of this standard had no impact within the unaudited condensed consolidated statement of cash flows for the three months ended March 26, 2016 . In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The standard reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification within the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted this standard d uring the three months ended April 1, 2017 , and applied the changes as required by each amendment to its consolidated financial statements and related disclosures. Under ASU 2016-09, the Company adopted the amendment to recognize excess tax benefits and tax deficiencies in the consolidated statement of income on a prospective basis, the amendment to present excess tax benefits within operating activities within the unaudited condensed consolidated statements of cash flows on a retrospective basis, and elected to change its accounting policy to account for forfeitures when they occur on a modified retrospective basis. The adoption to recognize excess tax benefits and tax deficiencies within the unaudited condensed consolidated statements of income on a prospective basis could result in fluctuations in the effective tax rate period-over-period depending on how many awards vest and the volatility of the stock price. During the three months ended April 1, 2017 , the impact to the provision for income taxes within the unaudited condensed consolidated statements of income was an excess tax benefit of $ 7.5 million . Further, for the three months ended April 1, 2017 , the Company excluded the effect of windfall tax benefits from the hypothetical proceeds used to calculate the repurchase of shares under the treasury stock method for the calculation of diluted earnings per share. The adoption of the amendment to present excess tax benefits within operating activities within the unaudited condensed consolidated statements of cash flows on a retrospective basis resulted in the reclassification of a cash inflow of $7.4 million from cash provided by financing activities to cash provided by operating activities for the three months ended March 26, 2016 . The Company had previously classified cash paid for tax withholding purposes as a financing activity within the unaudited condensed consolidated statements of cash flows; therefore, there was no change related to this requirement under the amendment. The Company’s election to change its accounting policy to account for forfeitures when they occur on a modified retrospective basis resulted in an immaterial impact to its consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2017, the FASB issued ASU 2017-07, “Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” The standard requires an employer to disaggregate the service cost component from the other components of net benefit cost and provides explicit guidance on the presentation of the service cost component and the other components of net benefit cost in the statement of income. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years, and should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost in the statement of income. Early adoption is permitted within the first interim period of the fiscal year. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. The ASU is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-01, “Clarifying the Definition of a Business.” The standard clarifies the definition of a business by adding guidance to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted for certain transactions. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In October 2016, the FASB issued ASU 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory.” The standard requires the immediate recognition of tax effects for an intra-entity asset transfer other than inventory. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures, but expects to recognize substantially all of its leases on the balance sheet by recording a right-to-use asset and a corresponding lease liability.

Business Acquisitions and Div23

Business Acquisitions and Divestiture (Tables)	3 Months Ended
	Apr. 01, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The purchase price allocation of $577.4 million , net of $27.4 million of cash acquired, was as follows: April 4, 2016 (in thousands) Trade receivables (contractual amount of $48,625) $ 48,157 Inventories 2,296 Other current assets (excluding cash) 3,814 Property, plant and equipment 129,066 Other long-term assets 1,060 Definite-lived intangible assets 164,800 Goodwill 330,175 Deferred revenue (39,103 ) Other current liabilities (27,386 ) Long-term liabilities (35,488 ) Total purchase price allocation $ 577,391 The purchase price allocation of $11.7 million , net of a non-significant amount of cash acquired, was as follows: June 27, 2016 (in thousands) Trade receivables (contractual amount of $1,104) $ 1,104 Other current assets (excluding cash) 15 Property, plant and equipment 912 Other long-term assets 187 Definite-lived intangible assets 1,230 Goodwill 10,477 Current liabilities (1,132 ) Long-term liabilities (1,044 ) Total purchase price allocation $ 11,749 The purchase price allocation of $62.0 million , net of $2.9 million of cash acquired, was as follows: September 28, 2016 (in thousands) Trade receivables (contractual amount of $4,799) $ 4,799 Other current assets (excluding cash) 1,509 Property, plant and equipment 3,907 Other long-term assets 11 Definite-lived intangible assets 21,900 Goodwill 43,899 Current liabilities (3,987 ) Long-term liabilities (10,013 ) Total purchase price allocation $ 62,025
Definite-Lived Intangible Assets Acquired as Part of Business Combination	The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 650 10 Other intangible assets 580 5 Total definite-lived intangible assets $ 1,230 7 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,700 17 Other intangible assets 5,200 4 Total definite-lived intangible assets $ 21,900 14 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 137,500 15 Developed technology 20,700 3 Backlog 6,600 1 Total definite-lived intangible assets $ 164,800 13
Carrying Amounts of Assets and Liabilities	As of February 10, 2017 , the carrying amounts of the major classes of assets and liabilities associated with the divestiture of the CDMO business were as follows: February 10, 2017 (in thousands) Assets Current assets $ 5,505 Property, plant and equipment, net 11,174 Goodwill 35,857 Long-term assets 17,154 Total assets $ 69,690 Liabilities Deferred revenue $ 4,878 Other current liabilities 1,158 Total liabilities $ 6,036

Supplemental Balance Sheet In24

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Apr. 01, 2017
Supplemental Balance Sheet Information [Abstract]
Composition of Net Trade Receivables	The composition of trade receivables, net is as follows: April 1, 2017 December 31, 2016 (in thousands) Client receivables $ 301,246 $ 283,997 Unbilled revenue 84,843 82,203 Total 386,089 366,200 Less: Allowance for doubtful accounts (2,341 ) (2,150 ) Trade receivables, net $ 383,748 $ 364,050
Composition of Inventories	The composition of inventories is as follows: April 1, 2017 December 31, 2016 (in thousands) Raw materials and supplies $ 18,401 $ 18,893 Work in process 10,851 13,681 Finished products 69,230 63,259 Inventories $ 98,482 $ 95,833
Composition of Other Current Assets	The composition of other current assets is as follows: April 1, 2017 December 31, 2016 (in thousands) Investments $ 3,872 $ 3,771 Prepaid income taxes 39,462 40,705 Restricted cash 538 532 Other current assets $ 43,872 $ 45,008
Composition of Other Assets	The composition of other assets is as follows: April 1, 2017 December 31, 2016 (in thousands) Life insurance policies $ 30,759 $ 29,456 Venture capital investments 48,789 45,331 Restricted cash 1,765 1,736 Other 12,549 11,907 Other assets $ 93,862 $ 88,430
Composition of Other Current Liabilities	The composition of other current liabilities is as follows: April 1, 2017 December 31, 2016 (in thousands) Accrued income taxes $ 17,880 $ 25,621 Other 580 879 Other current liabilities $ 18,460 $ 26,500
Composition of Other Long-Term Liabilities	The composition of other long-term liabilities is as follows: April 1, 2017 December 31, 2016 (in thousands) Long-term pension liability $ 89,047 $ 89,984 Accrued executive supplemental life insurance retirement plan and deferred compensation plan 33,213 32,880 Other 38,403 36,375 Other long-term liabilities $ 160,663 $ 159,239

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Apr. 01, 2017
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below: April 1, 2017 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 21 $ — $ 21 Other assets: Life insurance policies — 23,386 — 23,386 Total assets measured at fair value $ — $ 23,407 $ — $ 23,407 Other current liabilities: Contingent consideration $ — $ — $ 3,201 $ 3,201 Total liabilities measured at fair value $ — $ — $ 3,201 $ 3,201 December 31, 2016 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 21 $ — $ 21 Other assets: Life insurance policies — 22,121 — 22,121 Total assets measured at fair value $ — $ 22,142 $ — $ 22,142 Other current liabilities: Contingent consideration $ — $ — $ 3,621 $ 3,621 Total liabilities measured at fair value $ — $ — $ 3,621 $ 3,621
Fair Value, Contingent Consideration	The following table provides a rollforward of the contingent consideration related to the business acquisitions. See Note 2, “Business Acquisitions and Divestiture.” Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 3,621 $ 1,370 Additions — 600 Payments (406 ) (674 ) Total gains or losses (realized/unrealized): Reversal of previously recorded contingent liability and change in fair value (14 ) 18 Ending balance $ 3,201 $ 1,314

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Apr. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward of Goodwill	The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 31, 2016 Acquisitions / (Divestitures) Transfers Foreign Exchange April 1, 2017 (in thousands) DSA $ 563,476 $ (427 ) $ — $ 3,074 $ 566,123 RMS 56,397 — — 182 56,579 Manufacturing 167,644 (35,857 ) — 1,533 133,320 Total $ 787,517 $ (36,284 ) $ — $ 4,789 $ 756,022
Schedule of Intangible Assets	The following table displays intangible assets, net by major class: April 1, 2017 December 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 7,782 $ (7,351 ) $ 431 $ 8,370 $ (6,390 ) $ 1,980 Technology 72,241 (17,171 ) 55,070 71,425 (14,314 ) 57,111 Trademarks and trade names 8,271 (4,204 ) 4,067 8,177 (4,124 ) 4,053 Other 16,794 (6,026 ) 10,768 16,775 (5,628 ) 11,147 Other intangible assets 105,088 (34,752 ) 70,336 104,747 (30,456 ) 74,291 Client relationships 506,406 (206,929 ) 299,477 519,123 (198,966 ) 320,157 Intangible assets $ 611,494 $ (241,681 ) $ 369,813 $ 623,870 $ (229,422 ) $ 394,448

Long-Term Debt and Capital Le27

Long-Term Debt and Capital Lease Obligations (Tables)	3 Months Ended
	Apr. 01, 2017
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt, net consists of the following: April 1, 2017 December 31, 2016 (in thousands) Term loans $ 625,625 $ 633,750 Revolving credit facility 544,954 578,759 Other long-term debt 3,634 185 Total debt 1,174,213 1,212,694 Less: current portion of long-term debt (24,562 ) (24,560 ) Long-term debt 1,149,651 1,188,134 Debt discount and debt issuance costs (7,163 ) (7,633 ) Long-term debt, net $ 1,142,488 $ 1,180,501

Equity and Redeemable Noncont28

Equity and Redeemable Noncontrolling Interest (Tables)	3 Months Ended
	Apr. 01, 2017
Equity [Abstract]
Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Numerator: Income from continuing operations, net of income taxes $ 46,963 $ 37,575 Loss from discontinued operations, net of income taxes (4 ) (26 ) Less: Net income attributable to noncontrolling interests 181 406 Net income attributable to common shareholders $ 46,778 $ 37,143 Denominator: Weighted-average shares outstanding - Basic 47,546 46,642 Effect of dilutive securities: Stock options, restricted stock units, performance share units and restricted stock 875 975 Weighted-average shares outstanding - Diluted 48,421 47,617
Schedule of Accumulated Other Comprehensive Income	Changes to each component of accumulated other comprehensive income, net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 31, 2016 $ (154,595 ) $ (99,169 ) $ (253,764 ) Other comprehensive loss before reclassifications 11,104 — 11,104 Amounts reclassified from accumulated other comprehensive income (loss) — 854 854 Net current period other comprehensive income 11,104 854 11,958 Income tax expense — 226 226 April 1, 2017 $ (143,491 ) $ (98,541 ) $ (242,032 )
Rollforward Redeemable Noncontrolling Interest	The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interest: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 14,659 $ 28,008 Purchase of additional equity interest — — Total gains or losses (realized/unrealized): Net income (loss) attributable to noncontrolling interest (78 ) 198 Foreign currency translation 117 (186 ) Change in fair value, included in additional paid-in capital — 724 Ending balance $ 14,698 $ 28,744

Pension and Other Post-Retire29

Pension and Other Post-Retirement Benefit Plans Employee Benefits (Tables)	3 Months Ended
	Apr. 01, 2017
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Periodic Cost	The following table provides the components of net periodic cost for the Company’s Pension, Deferred Compensation, and Executive Supplemental Life Insurance Retirement plans: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Service cost $ 754 $ 554 Interest cost 2,826 3,364 Expected return on plan assets (3,450 ) (3,992 ) Amortization of prior service credit (119 ) (144 ) Amortization of net loss 966 546 Net periodic cost $ 977 $ 328

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Apr. 01, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense	The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Cost of revenue $ 1,546 $ 1,682 Selling, general and administrative 7,940 8,259 Stock-based compensation, before income taxes 9,486 9,941 Provision for income taxes (3,308 ) (3,514 ) Stock-based compensation, net of income taxes $ 6,178 $ 6,427

Foreign Currency Contracts (Tab

Foreign Currency Contracts (Tables)	3 Months Ended
	Apr. 01, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	The following table summarizes gains recognized on foreign exchange forward contracts related to intercompany loans denominated in Euros on the Company’s unaudited condensed consolidated statements of income: Three Months Ended Location of Gain (Loss) April 1, 2017 March 26, 2016 (in thousands) Other income (expense), net $ — $ 2,243

Restructuring and Asset Impai32

Restructuring and Asset Impairment (Tables)	3 Months Ended
	Apr. 01, 2017
Restructuring and Related Activities [Abstract]
Rollforward of Company's Severance and Retention Costs Liability	The following table provides a rollforward of the Company’s severance and transition costs liabilities related to those initiatives: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Beginning balance $ 3,680 $ 2,969 Expense 1,017 21 Payments / utilization (1,273 ) (413 ) Foreign currency adjustments 27 (56 ) Ending balance $ 3,451 $ 2,521
Schedule of Severance and Retention Costs	The following presents severance and transition related costs by reportable segment: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) DSA $ 196 $ 21 Manufacturing 821 — Total severance and transition costs $ 1,017 $ 21 The following table presents severance and transition costs by classification on the unaudited condensed consolidated statements of income: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Cost of services provided and products sold (excluding amortization of intangible assets) $ 923 $ 21 Selling, general and administrative 94 — Total severance and transition costs $ 1,017 $ 21

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Apr. 01, 2017
Segment Reporting [Abstract]
Schedule of Revenue and Other Financial Information by Business Segment	The following table presents revenue and other financial information by reportable segment: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) RMS Revenue $ 127,161 $ 123,339 Operating income 37,711 36,386 Depreciation and amortization 5,092 5,250 Capital expenditures 2,603 1,053 DSA Revenue $ 227,758 $ 157,983 Operating income 38,660 30,830 Depreciation and amortization 19,369 11,957 Capital expenditures 8,323 4,707 Manufacturing Revenue $ 90,844 $ 73,546 Operating income 26,601 19,615 Depreciation and amortization 5,962 5,976 Capital expenditures 2,292 2,129
Reconciliation of Segment Operating Income to Consolidated Operating Income	For the three months ended April 1, 2017, and March 26, 2016 , reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures April 1, 2017 March 26, 2016 April 1, 2017 March 26, 2016 April 1, 2017 March 26, 2016 (in thousands) Total reportable segments $ 102,972 $ 86,831 $ 30,423 $ 23,183 $ 13,218 $ 7,889 Unallocated corporate (33,500 ) (35,359 ) 1,988 1,472 2,702 361 Total consolidated $ 69,472 $ 51,472 $ 32,411 $ 24,655 $ 15,920 $ 8,250
Schedule of Net Sales for Each Significant Product or Service Offering	Revenue for each significant product or service offering is as follows: Three Months Ended April 1, 2017 March 26, 2016 (in thousands) RMS $ 127,161 $ 123,339 DSA 227,758 157,983 Manufacturing 90,844 73,546 Total revenue $ 445,763 $ 354,868
Summary of Unallocated Corporate Overhead	A summary of unallocated corporate expense consists of the following : Three Months Ended April 1, 2017 March 26, 2016 (in thousands) Stock-based compensation $ 5,583 $ 6,108 Compensation, benefits, and other employee-related expenses 14,962 12,541 External consulting and other service expenses 5,767 5,176 Information technology 2,393 3,132 Depreciation 1,987 1,472 Acquisition and integration 21 3,763 Other general unallocated corporate 2,787 3,167 Total unallocated corporate expense $ 33,500 $ 35,359

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016	Dec. 31, 2016	Dec. 26, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 445,763	$ 354,868
Restricted cash combined with unrestricted cash	133,827	159,321	$ 119,894	$ 119,963
Impact to income statement from recognition of excess tax benefits and tax deficiencies	7,500
Net cash provided by operating activities	34,029	45,844
Net cash provided by financing activities	(74,324)	(294)
Operating income	69,472	51,472
Accounting Standards Update 2016-09
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net cash provided by operating activities		(7,400)
Net cash provided by financing activities		(7,400)
Accounting Standards Update 2016-18 | New Accounting Pronouncement, Early Adoption, Effect
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Restricted cash combined with unrestricted cash		1,900		$ 2,000
Operating segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating income	102,972	86,831
Operating segments | Research Models and Services [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	127,161	123,339
Operating income	$ 37,711	36,386
Operating segments | Restatement Adjustment [Member] | Research Models and Services [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue		(700)
Operating income		$ (100)

Business Acquisitions and Div35

Business Acquisitions and Divestiture - Agilux Additional Information (Details) - Agilux Laboratories - USD ($) $ in Thousands	Sep. 28, 2016	Apr. 01, 2017
Business Acquisition [Line Items]
Purchase price	$ 64,900
Purchase price allocation	62,025
Cash acquired	$ 2,900
Integration related costs and transaction costs		$ 200

Business Acquisitions and Div36

Business Acquisitions and Divestiture - Agilux Purchase Price Allocation (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016	Sep. 28, 2016
Business Acquisition [Line Items]
Goodwill	$ 756,022	$ 787,517
Agilux Laboratories
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 4,799
Trade receivables			4,799
Other current assets (excluding cash)			1,509
Property, plant and equipment			3,907
Other long-term assets			11
Definite-lived intangible assets			21,900
Goodwill			43,899
Other current liabilities			(3,987)
Long-term liabilities			(10,013)
Total purchase price allocation			$ 62,025

Business Acquisitions and Div37

Business Acquisitions and Divestiture - Agilux Definite-Lived Intangible Assets (Details) - Agilux Laboratories $ in Thousands	Sep. 28, 2016USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 21,900
Weighted Average Amortization Life	14 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 16,700
Weighted Average Amortization Life	17 years
Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 5,200
Weighted Average Amortization Life	4 years

Business Acquisitions and Div38

Business Acquisitions and Divestiture - Blue Stream Additional Information (Details) - Blue Stream Laboratories - USD ($) $ in Thousands	Jun. 27, 2016	Apr. 01, 2017
Business Acquisition [Line Items]
Purchase price	$ 11,700
Maximum contingent consideration	3,000
Purchase price allocation	$ 11,749
Integration related costs and transaction costs		$ 0

Business Acquisitions and Div39

Business Acquisitions and Divestiture - Blue Stream Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jun. 27, 2016	Apr. 01, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 756,022	$ 787,517
Blue Stream Laboratories
Business Acquisition [Line Items]
Cash acquired	$ 0
Trade receivables, contractual amount	1,104
Trade receivables	1,104
Other current assets (excluding cash)	15
Property, plant and equipment	912
Other long-term assets	187
Definite-lived intangible assets	1,230
Goodwill	10,477
Current liabilities	(1,132)
Long-term liabilities	(1,044)
Total purchase price allocation	$ 11,749

Business Acquisitions and Div40

Business Acquisitions and Divestiture - Blue Stream Definite Lived Intangible Assets (Details) - Blue Stream Laboratories $ in Thousands	Jun. 27, 2016USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 1,230
Weighted Average Amortization Life	7 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 650
Weighted Average Amortization Life	10 years
Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 580
Weighted Average Amortization Life	5 years

Business Acquisitions and Div41

Business Acquisitions and Divestiture - WIL Research Additional Information (Details) - WIL Research - USD ($) $ in Thousands	Apr. 04, 2016	Apr. 01, 2017	Mar. 26, 2016	Feb. 11, 2017	Feb. 10, 2017
Business Acquisition [Line Items]
Purchase price	$ 604,800
Assumed liabilities	400
Purchase price allocation	577,391
Cash acquired	$ 27,400
Goodwill, expected tax deductible amount				$ 14,800	$ 19,000
Integration related costs and transaction costs		$ 500	$ 4,000

Business Acquisitions and Div42

Business Acquisitions and Divestiture - WIL Research Purchase Price Allocation (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016	Apr. 04, 2016
Business Acquisition [Line Items]
Goodwill	$ 756,022	$ 787,517
WIL Research
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 48,625
Trade receivables			48,157
Inventories			2,296
Other current assets (excluding cash)			3,814
Property, plant and equipment			129,066
Other long-term assets			1,060
Definite-lived intangible assets			164,800
Goodwill			330,175
Deferred revenue			(39,103)
Other current liabilities			(27,386)
Long-term liabilities			(35,488)
Total purchase price allocation			$ 577,391

Business Acquisitions and Div43

Business Acquisitions and Divestiture - WIL Research Definite Lived Intangible Assets (Details) - WIL Research $ in Thousands	Apr. 04, 2016USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 164,800
Weighted Average Amortization Life	13 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 137,500
Weighted Average Amortization Life	15 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 20,700
Weighted Average Amortization Life	3 years
Backlog
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 6,600
Weighted Average Amortization Life	1 year

Business Acquisitions and Div44

Business Acquisitions and Divestiture - Contract Manufacturing, Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016	Feb. 10, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on divestiture	$ 10,577	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received from divestiture			$ 75,000
Cash and cash equivalents transferred			600
Working capital adjustments			$ 300
Gain on divestiture	$ 10,600

Business Acquisitions and Div45

Business Acquisitions and Divestiture - Contract Manufacturing, Schedule of Assets and Liabilities Disposed (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Feb. 10, 2017	Dec. 31, 2016
Liabilities
Deferred revenue	$ 1,626		$ 1,623
Other current liabilities	$ 5,300		$ 5,771
CDMO Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Assets
Current assets		$ 5,505
Property, plant and equipment, net		11,174
Goodwill		35,857
Long-term assets		17,154
Total assets		69,690
Liabilities
Deferred revenue		4,878
Other current liabilities		1,158
Total liabilities		$ 6,036

Supplemental Balance Sheet In46

Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016	Mar. 26, 2016
Composition of trade receivables
Client receivables	$ 301,246	$ 283,997
Unbilled revenue	84,843	82,203
Total	386,089	366,200
Less: Allowance for doubtful accounts	(2,341)	(2,150)
Trade receivables, net	383,748	364,050
Composition of inventories
Raw materials and supplies	18,401	18,893
Work in process	10,851	13,681
Finished products	69,230	63,259
Inventories	98,482	95,833
Composition of other current assets
Investments	3,872	3,771
Prepaid income taxes	39,462	40,705
Restricted cash	538	532	$ 159
Other current assets	43,872	45,008
Composition of other assets
Life insurance policies	30,759	29,456
Venture capital investments	48,789	45,331
Restricted cash	1,765	1,736	$ 1,787
Other	12,549	11,907
Other assets	93,862	88,430
Composition of other current liabilities
Accrued income taxes	17,880	25,621
Other		879
Other current liabilities	18,460	26,500
Composition of other long-term liabilities
Long-term pension liability	89,047	89,984
Accrued executive supplemental life insurance retirement plan and deferred compensation plan	33,213	32,880
Other	38,403	36,375
Other long-term liabilities	$ 160,663	$ 159,239

Venture Capital Investments and

Venture Capital Investments and Marketable Securities - Additional Information (Details) - USD ($)	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Schedule of Equity Method Investments [Line Items]
Committed contribution	$ 84,800,000
Venture capital investments	42,000,000
Dividends received	4,400,000	$ 0
Gain (loss) from venture capital investments	$ 4,200,000	$ 3,100,000
Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	0.70%
Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	12.00%

Fair Value - Fair Value of Asse

Fair Value - Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 21	$ 21
Other assets:
Life insurance policies	23,386	22,121
Total assets measured at fair value	23,407	22,142
Other current liabilities:
Contingent consideration	3,201	3,621
Total liabilities measured at fair value	3,201	3,621
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	21	21
Other assets:
Life insurance policies	23,386	22,121
Total assets measured at fair value	23,407	22,142
Other current liabilities:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities:
Contingent consideration	3,201	3,621
Total liabilities measured at fair value	$ 3,201	$ 3,621

Fair Value - Contingent Conside

Fair Value - Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 3,621	$ 1,370
Additions	0	600
Payments	(406)	(674)
Total gains or losses (realized/unrealized):
Reversal of previously recorded contingent liability and change in fair value	(14)	18
Ending balance	$ 3,201	$ 1,314

Goodwill and Intangible Asset50

Goodwill and Intangible Assets - Gross Carrying Amount and Accumulated Amortization of Goodwill (Details) $ in Thousands	3 Months Ended
	Apr. 01, 2017USD ($)
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	$ 787,517
Adjustments to Goodwill, Acquisitions/(Divestitures)	(36,284)
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	4,789
Gross carrying amount, balance at the end of the period	756,022
DSA
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	563,476
Adjustments to Goodwill, Acquisitions/(Divestitures)	(427)
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	3,074
Gross carrying amount, balance at the end of the period	566,123
RMS
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	56,397
Adjustments to Goodwill, Acquisitions/(Divestitures)	0
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	182
Gross carrying amount, balance at the end of the period	56,579
Manufacturing
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	167,644
Adjustments to Goodwill, Acquisitions/(Divestitures)	(35,857)
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	1,533
Gross carrying amount, balance at the end of the period	$ 133,320

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Apr. 01, 2017	Dec. 31, 2016
Other intangible assets
Gross		$ 611,494	$ 623,870
Accumulated Amortization		(241,681)	(229,422)
Net		369,813	394,448
Impairment charge	$ 1,900
Backlog
Other intangible assets
Gross		7,782	8,370
Accumulated Amortization		(7,351)	(6,390)
Net		431	1,980
Backlog | CDMO Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Other intangible assets
Decrease in intangible assets resulting from divestiture of business		300
Technology
Other intangible assets
Gross		72,241	71,425
Accumulated Amortization		(17,171)	(14,314)
Net		55,070	57,111
Trademarks and trade names
Other intangible assets
Gross		8,271	8,177
Accumulated Amortization		(4,204)	(4,124)
Net		4,067	4,053
Other
Other intangible assets
Gross		16,794	16,775
Accumulated Amortization		(6,026)	(5,628)
Net		10,768	11,147
Other intangible assets
Other intangible assets
Gross		105,088	104,747
Accumulated Amortization		(34,752)	(30,456)
Net		70,336	74,291
Client relationships
Other intangible assets
Gross		506,406	519,123
Accumulated Amortization		(206,929)	(198,966)
Net		299,477	$ 320,157
Client relationships | CDMO Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Other intangible assets
Decrease in intangible assets resulting from divestiture of business		$ 16,800

Long-Term Debt and Capital Le52

Long-Term Debt and Capital Lease Obligations - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total debt	$ 1,174,213	$ 1,212,694
Less: current portion of long-term debt	(24,562)	(24,560)
Long-term debt	1,149,651	1,188,134
Debt discount and debt issuance costs	(7,163)	(7,633)
Long-term debt, net	1,142,488	1,180,501
Term loans
Debt Instrument [Line Items]
Total debt	625,625	633,750
Revolving credit facility
Debt Instrument [Line Items]
Total debt	544,954	578,759
Other long-term debt
Debt Instrument [Line Items]
Total debt	$ 3,634	$ 185

Long-Term Debt and Capital Le53

Long-Term Debt and Capital Lease Obligations - Additional Information (Details)	Mar. 30, 2016USD ($)payment	Apr. 01, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 29, 2016USD ($)
Debt Instrument [Line Items]
Weighted average interest rate		2.07%	1.89%
Credit facility	$ 1,650,000,000			$ 1,300,000,000
Capitalized debt issuance costs	3,300,000
Expensed debt issuance costs	1,400,000
Maximum borrowing capacity, term loan and line of credit facility, potential increase available	$ 500,000,000
Credit facility
Debt Instrument [Line Items]
Minimum EBITDA less capital expenditures to consolidated cash interest expense ratio	3.50
Maximum consolidated indebtedness to consolidated EBITDA	4.25
Maximum consolidated indebtedness to consolidated EBITDA, with step-downs	3.50
Other Capital Lease Obligations
Debt Instrument [Line Items]
Other capital lease obligations		$ 30,300,000	$ 29,900,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding		$ 4,900,000	$ 4,900,000
Federal Funds Rate
Debt Instrument [Line Items]
Interest rate	0.50%
LIBOR
Debt Instrument [Line Items]
Interest rate	1.00%
Term Loan Facility
Debt Instrument [Line Items]
Credit facility	$ 650,000,000
Number of quarterly installment payments | payment	19
Multi-currency Revolving Facility
Debt Instrument [Line Items]
Credit facility	$ 1,000,000,000

Equity and Redeemable Noncont54

Equity and Redeemable Noncontrolling Interest - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Numerator:
Income from continuing operations, net of income taxes	$ 46,963	$ 37,575
Loss from discontinued operations, net of income taxes	(4)	(26)
Less: Net income attributable to noncontrolling interests	181	406
Net income attributable to common shareholders	$ 46,778	$ 37,143
Denominator:
Weighted-average shares outstanding—Basic (in shares)	47,546	46,642
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock (in shares)	875	975
Weighted-average shares outstanding—Diluted (in shares)	48,421	47,617

Equity and Redeemable Noncont55

Equity and Redeemable Noncontrolling Interest - Earnings Per Share, Additional Information (Details) - shares shares in Millions	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1.1	1
Restricted Stock and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1.1	1.1

Equity and Redeemable Noncont56

Equity and Redeemable Noncontrolling Interest - Treasury Shares (Details) - USD ($) shares in Millions	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016	May 09, 2017	May 08, 2017
Treasury Shares
Purchase of treasury stock	$ 48,180,000	$ 12,147,000
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	0.2	0.2
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 16,100,000	$ 12,100,000
Authorized Share Repurchase Program
Treasury Shares
Stock repurchased during period (in shares)	0.4
Purchase of treasury stock	$ 32,100,000
Remaining authorized repurchase amount	$ 37,600,000
Authorized Share Repurchase Program | Subsequent Event
Treasury Shares
Stock repurchase authorization			$ 1,300,000,000	$ 150,000,000

Equity and Redeemable Noncont57

Equity and Redeemable Noncontrolling Interest - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Other comprehensive loss before reclassifications	$ 11,104
Amounts reclassified from accumulated other comprehensive income (loss)	854
Net current period other comprehensive income	11,958
Income tax expense	226	$ 142
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 31, 2016	(154,595)
Other comprehensive loss before reclassifications	11,104
Amounts reclassified from accumulated other comprehensive income (loss)	0
Net current period other comprehensive income	11,104
Income tax expense	0
April 1, 2017	(143,491)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 31, 2016	(99,169)
Other comprehensive loss before reclassifications	0
Amounts reclassified from accumulated other comprehensive income (loss)	854
Net current period other comprehensive income	854
Income tax expense	226	$ 100
April 1, 2017	(98,541)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 31, 2016	(253,764)
April 1, 2017	$ (242,032)

Equity and Redeemable Noncont58

Equity and Redeemable Noncontrolling Interest - Redeemable Noncontrolling Interest, Additional Information (Details) - USD ($) $ in Millions	Apr. 01, 2017	Jul. 07, 2016	Jan. 31, 2013
Investment [Line Items]
Contractually defined redemption value	$ 14.1
Vital River
Investment [Line Items]
Ownership percentage	87.00%	12.00%	75.00%
Noncontrolling interest ownership percentage	13.00%

Equity and Redeemable Noncont59

Equity and Redeemable Noncontrolling Interest - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 14,659	$ 28,008
Purchase of additional equity interest	0	0
Total gains or losses (realized/unrealized):
Foreign currency translation	117	(186)
Ending balance	14,698	28,744
Net income (loss) attributable to noncontrolling interest
Total gains or losses (realized/unrealized):
Income (loss) attributable to noncontrolling interest	(78)	198
Change in fair value, included in additional paid-in capital
Total gains or losses (realized/unrealized):
Income (loss) attributable to noncontrolling interest	$ 0	$ 724

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Effective tax rate	39.80%	27.10%
Tax benefit associated with stock compensation	$ 7,500
Increase in unrecognized tax benefits	900
Unrecognized tax benefits	25,100
Increase in unrecognized tax benefits that would impact effective tax rate	800
Unrecognized tax benefits that would impact effective tax rate	22,200
Accrued interest and penalties on unrecognized tax benefits	1,900	$ 200
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period	5,000
Income tax expense	226	142
Pension and Other Post-Retirement Benefit Plans
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax expense	226	$ 100
CDMO Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Tax on gain on divestiture	$ 18,000

Pension and Other Post-Retire61

Pension and Other Post-Retirement Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Pension
Employee benefits
Service cost	$ 754	$ 554
Interest cost	2,826	3,364
Expected return on plan assets	(3,450)	(3,992)
Amortization of prior service credit	(119)	(144)
Amortization of net loss	966	546
Net periodic cost	977	328
Post-retirement Benefit Plan
Employee benefits
Net periodic cost	$ 0	$ 0

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 9,486	$ 9,941
Provision for income taxes	(3,308)	(3,514)
Stock-based compensation, net of income taxes	6,178	6,427
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	1,546	1,682
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 7,940	$ 8,259

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Grants (Details) shares in Millions	3 Months Ended
	Apr. 01, 2017$ / sharesshares
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0.6
Stock options weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.27
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 88.05
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 99.24
Maximum shares to be awarded under plan (in shares)	0.4

Foreign Currency Contracts - Ef

Foreign Currency Contracts - Effect on Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Other income (expense), net | Foreign Currency Forward Contract
Derivatives, Fair Value [Line Items]
Gain (loss) recognized	$ 0	$ 2,243

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Mar. 13, 2017	Apr. 01, 2017	Dec. 31, 2016	Dec. 26, 2015
Loss Contingencies [Line Items]
Increase in lease obligations		$ 6.1
Government billing
Loss Contingencies [Line Items]
Liability for estimated possible loss				$ 1.5
Increase in liability for estimated possible loss			$ 0.3
Payments to resolve litigation	$ 1.8

Restructuring and Asset Impai66

Restructuring and Asset Impairment - Rollforward of Severance and Retention Costs Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Restructuring Reserve [Roll Forward]
Beginning balance	$ 3,680	$ 2,969
Expense	1,017	21
Payments / utilization	(1,273)	(413)
Foreign currency adjustments	27	(56)
Ending balance	$ 3,451	$ 2,521

Restructuring and Asset Impai67

Restructuring and Asset Impairment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016	Dec. 31, 2016	Dec. 26, 2015
Restructuring Cost and Reserve [Line Items]
Severance and retention costs liability	$ 3,451	$ 2,521	$ 3,680	$ 2,969
Impairment charges	100
Gain on restructuring	400
Accelerated depreciation		200
Accrued Compensation
Restructuring Cost and Reserve [Line Items]
Severance and retention costs liability	3,500	2,400
Other Long-Term Liabilities
Restructuring Cost and Reserve [Line Items]
Severance and retention costs liability	$ 0	$ 0

Restructuring and Asset Impai68

Restructuring and Asset Impairment - Severance and Retention Costs by Classification on the Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	$ 1,017	$ 21
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	923	21
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	$ 94	$ 0

Restructuring and Asset Impai69

Restructuring and Asset Impairment - Severance and Retention Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Segment Reporting Information [Line Items]
Total severance and transition costs	$ 1,017	$ 21
DSA
Segment Reporting Information [Line Items]
Total severance and transition costs	196	21
Manufacturing
Segment Reporting Information [Line Items]
Total severance and transition costs	$ 821	$ 0

Segment Information - Revenue a

Segment Information - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Segment Reporting Information [Line Items]
Revenue	$ 445,763	$ 354,868
Operating income	69,472	51,472
Depreciation and amortization	32,411	24,655
Capital expenditures	15,920	8,250
Operating segments
Segment Reporting Information [Line Items]
Operating income	102,972	86,831
Depreciation and amortization	30,423	23,183
Capital expenditures	13,218	7,889
RMS | Operating segments
Segment Reporting Information [Line Items]
Revenue	127,161	123,339
Operating income	37,711	36,386
Depreciation and amortization	5,092	5,250
Capital expenditures	2,603	1,053
DSA | Operating segments
Segment Reporting Information [Line Items]
Revenue	227,758	157,983
Operating income	38,660	30,830
Depreciation and amortization	19,369	11,957
Capital expenditures	8,323	4,707
Manufacturing | Operating segments
Segment Reporting Information [Line Items]
Revenue	90,844	73,546
Operating income	26,601	19,615
Depreciation and amortization	5,962	5,976
Capital expenditures	$ 2,292	$ 2,129

Segment Information - Reconcili

Segment Information - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Segment Reporting Information [Line Items]
Operating income	$ 69,472	$ 51,472
Depreciation and amortization	32,411	24,655
Capital expenditures	15,920	8,250
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	102,972	86,831
Depreciation and amortization	30,423	23,183
Capital expenditures	13,218	7,889
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(33,500)	(35,359)
Depreciation and amortization	1,988	1,472
Capital expenditures	$ 2,702	$ 361

Segment Information - Revenue P

Segment Information - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Segment Reporting Information [Line Items]
Revenue	$ 445,763	$ 354,868
Operating segments | RMS
Segment Reporting Information [Line Items]
Revenue	127,161	123,339
Operating segments | DSA
Segment Reporting Information [Line Items]
Revenue	227,758	157,983
Operating segments | Manufacturing
Segment Reporting Information [Line Items]
Revenue	$ 90,844	$ 73,546

Segment Information - Summary o

Segment Information - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2017	Mar. 26, 2016
Segment Reporting Information [Line Items]
Stock-based compensation	$ 9,486	$ 9,941
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	5,583	6,108
Compensation, benefits, and other employee-related expenses	14,962	12,541
External consulting and other service expenses	5,767	5,176
Information technology	2,393	3,132
Depreciation	1,987	1,472
Acquisition and integration	21	3,763
Other general unallocated corporate	2,787	3,167
Total unallocated corporate expense	$ 33,500	$ 35,359